marked.bio

anti-HER2 antibody · antibody

pertuzumab

7 active trials across 8 of our biomarkers, targeting HER2. Not approved for any biomarker on marked.bio yet.

Also known as Perjeta.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
PIK3CA activating mutation 3 6 Phase 3
MSI-H / dMMR 2 3 Phase 3
BRCA1/2 mutation 1 2 Phase 2
HER2 (ERBB2) activating mutation 1 2 Phase 2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 2 Phase 1
ALK fusion 0 2 –
BRAF V600E 0 3 –
RET fusion or mutation 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of pertuzumab.

  1. Novartis 1
  2. Roche 1

Trials

7 of 15 trials shown

  1. Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

    Active, not recruiting Phase 3 Novartis Started 2020Primary completion 2027-02 NCT04208178

    alpelisib FDA EUtrastuzumabpertuzumab

    Applies only to Part 2: Participant has a PIK3CA mutation(s) present in tumor prior to enrollment, locally confirmed per test listed in protocol or…

    PIK3CA activating mutationAdvanced HER2+Breast Cancer

  2. Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

    Active, not recruiting Phase 3 Massachusetts General Hospital Started 2020Primary completion 2026-12 NCT03803553

    FOLFIRIleucovorinfluorouracilirinotecannivolumab FDA EUencorafenibbinimetinibcetuximabtrastuzumabpertuzumab

    Presence of deficient (d) DNA mismatch repair (dMMR) may be assessed by IHC for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of…

    MSI-H / dMMRMetastatic Colon Cancer, Stage III Colon Cancer

  3. Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

    Not yet recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2026Primary completion 2027-08 NCT07716111

    trastuzumabpertuzumab

    Biomarker Status: PD-L1 CPS ≥1, EBV-positive, or dMMR/MSI-H

    MSI-H / dMMRGastric or Gastroesophageal Junction Adenocarcinoma

  4. A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

    Not yet recruiting Phase 2 Zhimin Shao Started 2025Primary completion 2026-12 NCT07245797

    pertuzumabtrastuzumabnab-paclitaxelinavolisib FDA EU

    HER2+ disease with confirmed ER-status, PR-status, HER2-status, PIK3CA mutation (tumor), Ki-67 value on core biopsy (target lesion).

    PIK3CA activating mutationBreast Cancer

  5. Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

    Recruiting Phase 2 German Cancer Research Center Started 2023Primary completion 2030-03 NCT05332561

    atezolizumabinavolisibipatasertibolaparibsacituzumab govitecantrastuzumabpertuzumab

    Arm 6 (Trastuzumab / Pertuzumab, ERBBB): HER2 exon-20 insertion, Activating HER2-mutation

    HER2 (ERBB2) activating mutationBRCA1/2 mutationEarly-stage Breast Cancer

  6. Testing a New Imaging Agent to Identify Cancer

    Active, not recruiting Phase 1 Memorial Sloan Kettering Cancer Center Started 2020Primary completion 2027-11 NCT04692831

    pertuzumab

    Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer

  7. To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

    Active, not recruiting Phase 1 Roche Started 2016Primary completion 2026-12 NCT03006172

    inavolisib FDA EUfulvestrant FDA EUletrozolepalbociclib FDA EUmetformintrastuzumabpertuzumab

    Locally advanced, recurrent, or metastatic, PIK3CA mutant, incurable solid tumor malignancy, including breast cancer

    PIK3CA activating mutationBreast Cancer, Solid Tumor